Coherus Oncology (CHRS) Common Equity (2012 - 2026)

Coherus Oncology has disclosed Common Equity across 15 years of filings, most recently posting $60.8 million for Q2 2026.

• In Q2 2026, Common Equity fell 49.23% year-over-year to $60.8 million; the TTM figure through Jun 2026 stood at $60.8 million (down 49.23% YoY), while the FY2025 annual figure was $61.0 million, up 146.23% from the prior year.
• Common Equity came in at $60.8 million for Q2 2026 at Coherus Oncology, down from $78.6 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $119.8 million in Q2 2025 to a low of -$196.5 million in Q1 2023.
• Average Common Equity over 5 years is -$61.3 million, with a median of -$86.0 million recorded in 2024.
• Year-over-year, Common Equity sank 1664.17% in 2023 and soared 242.47% in 2025.
• Over 5 years, Common Equity stood at -$137.4 million in 2022, then plunged by 40.76% to -$193.4 million in 2023, then soared by 31.76% to -$132.0 million in 2024, then surged by 146.23% to $61.0 million in 2025, then declined by 0.29% to $60.8 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $60.8 million in Q2 2026, $78.6 million in Q1 2026, and $61.0 million in Q4 2025.